EMOST: elimination of chronic constipation and diarrhea by low-frequency and intensity electromagnetic fields

Previously, we reported about the effectiveness of the EMOST (Electro-Magnetic-Own-Signal-Treatment) treatments in reduction of phantom limb pain as well as improvement of the quality of sleep and mood in subjects under clinical circumstances. We also presented the successful application of EMOST for mental stress management of humans under catastrophic conditions. Our some years experience indicated that the efficiency of EMOST is much greater in children than in adult subjects. In addition, in children much less treatment is needed for recovery compared to adult subjects, as well as the duration of the treatment is shorter. It is possible that this particular success is due to the large plasticity of the central and the autonomic nervous system in young patients. Thus, our research pays special attention regarding the EMOST effectiveness in the field of chronic childhood diseases. Here we report about results of routine alternative treatments carried out at Biolabor Biophysics and Laboratory Services Ltd. by EMOST device regarding to the elimination of chronic constipation and persistent diarrhea in the case of two children. We also briefly present two important possible biological mechanisms such as redox processes and the bidirectional communication between skin cells and the nervous system regarding the efficiency of low-frequency and low-intensity electromagnetic fields (LFI-EMF) treatments.     

整肠生联合常乐康治疗伴肠道菌群失调功能性腹泻的疗效观察

目的观察整肠生、常乐康联合应用治疗伴有肠道菌群失调功能性腹泻的临床疗效及其对肠道定植抗力的影响。方法选取符合入组条件的门诊患者共64例,随机分为整肠生（A）组22例、整肠生＋常乐康（B）组21例、常乐康（C）组21例。1个月后观察各组临床疗效。结果改善消化道症状有效率整肠生组为55％,联合用药组为90％,常乐康组为55％;改善肠道整体菌群有效率分别为25％、70％、30％;改善B／E值有效率分别为65％、90％、60％。联合用药组与单独使用整肠生或常乐康组差异均有统计学意义（P〈0．05）。试验中三个治疗组均无明显不良反应事件发生。结论单独应用整肠生或常乐康、以及两药联合应用均能有效的改善功能性腹泻的症状、调整肠道菌群、增强肠道定植抗力,其中联合用药组的疗效更显著。     

微生态制剂联合小儿康治疗儿童迁延性腹泻机制研究

目的:探讨微生态制剂思连康联合小儿康治疗儿童迁延性腹泻的疗效,并进一步探讨其机制.方法:我院共收治60例腹泻患儿,随机分为两组,均在常规治疗基础上治疗组加用思连康联合小儿康,对照组加用杜拉宝治疗儿童腹泻.观察两组的疗效,以及两组临床症状的好转情况及住院时间的比较.酶联免疫吸附双抗体夹心法(ELISA法)检测两组患者血清和粪便白介素6和8(IL-6和IL-8)的变化.结果:治疗组总有效率为90％,高于对照组(P＜0.05);临床症状的好转情况及住院时间的比较优于对照组(P＜0.01).治疗后血清及大便细胞因子IL-6和IL-8均有降低,并优于对照组(P＜0.05).结论:思连康联合小儿康治疗儿童迁延性腹泻,疗效显著,值得广泛推广.其机制可能与下调炎性细胞因子有关.     

Cleavage of the NS2-3 protein in the cells of cattle persistently infected with non-cytopathogenic bovine viral diarrhea virus

The NS2-3 of BVDV is cleaved in cultured cells infected with cp BVDV but not in those infected with ncp BVDV when tested more than 10 hours post infection. However, it is not known whether cleavage of NS2-3 occurs in vivo. In the present study, cleavage of NS2-3 in cattle persistently infected with BVDV was investigated. All BVDV isolated from PI animals were of the ncp biotype, and NS2-3 proteins were detected in bovine fetal muscular cells infected with these viruses. On the other hand, in the leukocytes of those PI animals, NS3 proteins, products of the cleavage of NS2-3 proteins, were detected. In addition, the NS3 proteins were also detected in leukocytes artificially infected with ncp BVDV. These results reveal that the NS2-3 protein of BVDV is cleaved in leukocytes. Furthermore, NS3 proteins were detected in many tissues of PI cattle, such as lymphoid tissue, brain, thyroid, lung, and kidney. These results suggest that the NS2-3 protein of ncp BVDV cleaves in vivo.     

爽舒康片治疗急慢性腹泻64例的临床研究

目的:观察爽舒康片治疗急慢性腹泻的临床疗效和安全性.方法:采用多中心随机双盲对照试验.爽舒康片64例,po,0.7 g(7.0×108 CFU),tid;对照药米雅片65例,po,0.7 g(7.0×108 CFU),tid.疗程:急性腹泻3～7 d,慢性腹泻14～21 d.结果:爽舒康片治疗急性腹泻有效率为100%(31/31),慢性腹泻有效率为97.0%(32/33);对照药米雅片分别为100%(32/32)和100%(33/33).两药疗效间差异均无显著性(P＞0.05),也均未出现不良反应.结论:爽舒康片是治疗急性、慢性腹泻的安全有效的微生态制剂,其疗效和安全性均与进口药米雅片相当.     

计算机在确定牛病毒性腹泻病毒基因组常用限制性内切酶位点中的应用

应用计算机测定71种限制性内切酶在牛病毒性腹泻病毒NADL株(BVDV NADL)基因组的cDNA核苷酸序列中酶切位点,结果表明其中S8种酶的酶切位点所在的核苷酸序列数,也表明了其中13种限制性内切酶在核苷酸序列中无酶切位点。这些结果有助于进一步研究BVDV InL株的cDNA基因库。     

人源产肠毒素大肠杆菌疫苗的研发进展

腹泻是全球范围内引起5岁以下幼童死亡的第二大病因,而产肠毒素大肠杆菌(ETEC)是引起腹泻的最常见病原菌,其产生的细菌定植因子(CFs)和肠毒素是关键的毒力因子。CFs介导细菌黏附宿主小肠上皮细胞并完成定植,产生热敏肠毒素(LT)和热稳定肠毒素(ST)破坏宿主上皮细胞内的体液平衡,使体液和电介质过量分泌从而导致腹泻。预防ETEC腹泻的首选方法是使用能激发宿主产生抗黏附素免疫力和抗肠毒素免疫力的疫苗,阻断ETEC黏附和定植并中和肠毒素。目前一种名为Dukoral~的霍乱疫苗因能刺激机体产生抗热敏毒素免疫,已经被一些国家批准用于短期保护和预防旅行者腹泻。新型试验性ETEC候选疫苗正在研发中,旨在提供保护期长、反应谱广的抗ETEC感染免疫保护力。本文针对疫苗研发的关键问题和研究现状作一综述,并对未来的研究作出展望。